

Blood Products
2200 Northern Blvd.
East Hills, NY 11548 USA

516.484.5400 phone
516.484.8919 fax
800.645.6578 toll free
www.pall.com

January 24, 2005

Dear Pall Customer,

This week, Pall Medical will provide an update to the industry at the January 25th Blood Safety and Availability Committee (BSAC) Meeting in Washington, D.C. on the topic of the Pall BPF4TM Filter System field action. We are also seeking a BSAC recommendation in support of developing a reference standard to measure plasma free hemoglobin in stored red blood cells. In case you are unable to attend this meeting, we wanted you to be aware that Pall is also committed to working together with the AABB Standards Committee and other leading industry organizations to accomplish this objective.

As you know, last month we issued a voluntary limited recall of 24 lot numbers of Pall BPF4 Filter Systems and have continued to carry out testing and evaluation of the root cause of hemolysis in leukoreduced products. Most importantly, no adverse reactions have been reported at any time throughout the investigation.

Presently, there is still no definitive answer, however we are pleased to report that there are also no significant reports of hemolysis events among product users since the January 5th webcast update. The cumulative occurrence rate continues to decline as more filters are used without incident. At his time, 98% of Pall BPF4 Filter System users have continued to use this leukoreduction system with no reported problems.


We continue to investigate a root cause linked to a possible variability in the wetting or priming of the filters. As we collect more data to support this working hypothesis, we have put appropriate manufacturing process monitors in place as a precautionary measure. We are working very closely with the FDA to resolve any issues as expeditiously as possible and are confident that the return of potentially implicated filter lots has minimized any impact on blood safety and availability.

To continue keeping you updated on this matter and future communications, we would greatly appreciate your confirming your contact information (name, mailing/email address) by calling our toll-free Customer Care Hotline at 800.645.6578 or by sending an email to marie_granieri@pall.com. This information will be entered into our customer contact database that we are currently updating.

Your time and cooperation in the investigation of the implicated lot numbers and units has been most valuable to all concerned. We thank you for your patience and support.

Please continue to contact us by phone at 800.645.6578 or through the Pall website at www.pall.com/medical_info.asp with questions or observations.

Sincerely,



Hal Baker
Senior Vice President, Pall Medical
Phone: 516.801.9551
Mobile: 516.445.7400
Email: hal_baker@pall.com